

1 **Prescribing pre-exposure prophylaxis (PrEP) for HIV prevention: A cross-sectional survey**
2 **of General Practitioners in Australia**

3 Jason Wu^{1,2}, Christopher K. Fairley^{2,3}, Daniel Grace⁴, Benjamin R. Bavinton⁵, Doug Fraser⁵,
4 Curtis Chan⁵, Eric P.F. Chow^{2,3,6*}, Jason J. Ong^{2,3,6,7*}

5

6 ¹ Kings Park Medical Centre - Hillside, General Practice, Melbourne, Vic., Australia

7 ² Melbourne Sexual Health Centre, Alfred Health, Melbourne, Vic., Australia

8 ³ Central Clinical School, Monash University, Melbourne, Australia

9 ⁴ University of Toronto, Dalla Lana School of Public Health, Toronto, Canada

10 ⁵ Kirby Institute, The University of New South Wales, New South Wales, Australia

11 ⁶ Melbourne School of Population & Global Health, The University of Melbourne, Melbourne,
12 Australia

13 ⁷ Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine,
14 London, United Kingdom

15 * Co-senior authors

16

17 Corresponding author

18 Jason Wu

19 40 Gourlay Road,

20 Hillside VIC 3037.

21 Phone: +613 9217 9400

22 Email: jasun_quo@hotmail.com

23

24

25

26 **ABSTRACT**

27

28 **Background**

29 Pre-exposure prophylaxis (PrEP) is a safe and effective medication for preventing HIV
30 acquisition. We examined Australian general practitioners' (GP) knowledge of PrEP efficacy,
31 characteristics associated with ever prescribing PrEP, and barriers to prescribing.

32 **Methods**

33 We conducted an online cross-sectional survey of GPs working in Australia between April and
34 October 2022. We performed univariable and multivariable logistic regression analyses to
35 identify factors associated with: 1) the belief that PrEP was at least 80% efficacious; and 2)
36 ever prescribed PrEP. We asked participants to rate the extent to which barriers affected their
37 prescribing of PrEP.

38 **Results**

39 407 participants with a median age of 38 years (interquartile range 33-44). Half of the
40 participants (50%, 205/407) identified how to correctly take PrEP, 63% (258/407) had ever
41 prescribed PrEP, and 45% (184/407) felt confident with prescribing PrEP. Ever prescribing
42 PrEP was associated with younger age (AOR 0.97, 95%CI: 0.94-0.99), extra training in sexual
43 health (AOR 2.57, 95%CI: 1.54-4.29), and being a S100 Prescriber (OR 2.95, 95%CI: 1.47-
44 5.90). The main barriers to prescribing PrEP included: 'Difficulty identifying clients who
45 require PrEP/relying on clients to ask for PrEP' (76%, 310/407), 'Lack of knowledge about
46 PrEP' (70%, 286/407), and 'Lack of time' (69%, 281/407).

47 **Conclusion**

48 Less than half of our GP respondents were confident in prescribing PrEP, and most had
49 difficulty identifying who would require PrEP. Specific training on PrEP, which focuses on
50 PrEP knowledge, identifying suitable clients, and making it time efficient is recommended,
51 with GPs being remunerated for their time.

52

53

54

55

56 INTRODUCTION

57

58 Studies have shown that pre-exposure prophylaxis (PrEP) is up to 99% effective at reducing
59 HIV infection by sexual transmission and is safe (1, 2). The Joint United Nations Programme
60 on HIV/AIDS (UNAIDS) has set a declaration to end the AIDS epidemic by 2030, and one of
61 the targets to accomplish this goal is to ensure the availability of PrEP for 10 million people
62 at substantial risk of HIV by 2025 (3).

63

64 Most GPs in Australia have no or limited experience in HIV treatment and prevention. There
65 were 39,736 GPs working in Australia in 2022/23 (4), and as of January 2024 there are only
66 265 HIV S100 prescribers (able to prescribe HIV treatment) with only a proportion of these
67 being GPs (5). There are only 114 sexual health physicians working in Australia, with the
68 majority working in major cities (6). Any doctor or nurse practitioner in Australia can
69 prescribe PrEP, which has been on the Australian government's Pharmaceutical Benefits
70 Scheme (PBS) since April 2018. The PBS subsidises the cost of certain medications so that
71 PrEP costs AU\$30 for 30 pills or \$7.30 for people with a concession card. There have been
72 18,217 individual prescribers who have prescribed PrEP in Australia (7).

73

74 Past studies have identified several barriers to PrEP prescribing among GPs. Barriers include
75 lack of knowledge regarding PrEP, inability to identify clients at risk of HIV, and concern that
76 PrEP use may increase the incidence of other STIs (8, 9, 10, 11, 12). An Australian GP
77 questionnaire found the main barriers to PrEP prescribing were lack of experience with
78 antiretrovirals and lack of guidelines for prescription (13). Another Australian study involving
79 interviews with 51 healthcare professionals identified barriers such as attributing PrEP to
80 'promiscuity' and a belief that condom use was satisfactory HIV prevention (14).

81

82 These studies on PrEP perspectives among health professionals were either qualitative or
83 were conducted before PrEP was available on the PBS for GPs to prescribe. We sought to
84 conduct a quantitative study looking at GP knowledge of PrEP, confidence with prescribing
85 and the barriers to prescribing.

86

87 **METHODS**

88

89 **Study population and recruitment**

90 We distributed this anonymous online survey to GPs, GP registrars and trainees in Australia
91 between April 14th and October 13th, 2022. Participants were eligible if they lived in
92 Australia. Other exclusion criteria included having answers that were unusual for the
93 question, and if <90% of the questions were answered. The survey link was disseminated via
94 a Facebook group for Australian GPs, the Royal Australian College of General Practitioners,
95 Melbourne Sexual Health Centre and Public Health Networks. This was a voluntary survey,
96 and completion of the survey implied consent. Participants could opt-in to win one of five
97 \$300 vouchers.

98

99 **Survey instrument**

100 Respondents accessed the survey through an online link (hosted by Qualtrics). We utilized a
101 KAP (Knowledge, Attitudes and Practices) survey model to structure our questions (15). The
102 survey collected data on sociodemographic characteristics and assessed their knowledge of
103 PrEP. Respondents were given five options for each question, with the complete questions
104 and options listed in Supplementary File 1.

105

106 Respondents were asked how likely they were to prescribe PrEP to hypothetical clients from
107 certain groups, with responses as a Likert scale (not at all, unlikely, likely, highly likely,
108 certain). The groups included: '*Sexually active males who have anal sex with males without*
109 *condoms*', '*Sexually active males who have anal sex with males and report condom use*',
110 '*Sexually active heterosexual males and females at increased risk of HIV transmission*',
111 '*People who inject drugs*', '*Serodiscordant couples (i.e. one partner HIV positive and the*
112 *other HIV negative)*', and '*Sex workers*'. These questions were adapted from an Australian
113 study (13).

114

115 They were also asked how much certain barriers affect their ability to prescribe PrEP, with
116 responses as a Likert scale (not affected, slightly affected, moderately affected, very

117 affected, unsure). The barriers included *'Lack of knowledge about PrEP'*, *'Lack of time to*
118 *adequately counsel about PrEP'*, *'Unsure where to look for resources on PrEP'*, *'Resources on*
119 *PrEP difficult to use/interpret'*, *'Difficulty identifying which clients would require PrEP /*
120 *relying on clients to ask for PrEP'*, *'Lack of experience or hesitation in prescribing antivirals'*,
121 *'Difficulty in finding an entry point to asking clients about their risk of HIV/sexual history'*,
122 *'Concern that promoting PrEP may increase risk of other STIs'*, *'Concern that the client may*
123 *not take PrEP properly / be non-compliant'*, *'Discomfort with managing people who identify*
124 *as LGBTIQ'*. Respondents were also allowed to list other barriers via free text entry.

125 There were additional questions about how often GPs prescribed PrEP, how confident they
126 felt when prescribing, and how often they took clients' sexual history, with full details in
127 Supplementary File 1.

128

129 **Statistical analysis**

130 We used descriptive statistics to summarise the characteristics of the study participants.
131 Logistic regression analyses were used to identify factors associated with two outcomes: 1)
132 belief that PrEP was at least 80% efficacious; and 2) ever prescribed PrEP. Variables were
133 initially included in the multivariable model if the p value was <0.20 in the univariable analysis.
134 Using complete case analysis, we used a backward elimination approach to derive the final
135 multivariable model. We reported both crude and adjusted odds ratio, 95% confidence
136 interval. Statistical significance was defined as having a p value of <0.05. Statistical analyses
137 were performed using Stata (version 17, StataCorp, College Station, TX).

138

139 **Ethics approval**

140 Ethics approval was obtained from the Alfred Ethics Committee, Melbourne, Australia
141 (166/22).

142

143

144 **RESULTS**

145 We received 703 survey respondents, but 90 were excluded as they had answers that were
146 unusual e.g. a question asking about barriers to PrEP prescribing yielded an answer of *'The*
147 *prediction method of the expanded algorithm'*. A further 171 were excluded as they were
148 completed in countries outside Australia, and 35 were excluded because the number of
149 questions answered was <90%. The sociodemographic characteristics of the 407 participants
150 are detailed in our other study (16). Briefly, the median age of the participants was 38, with
151 an interquartile range (IQR) of 33-44. The median years of practising as a GP was 6, with an
152 IQR of 4-12.

153

154 **Test of Knowledge**

155 Only 50.4% (205/407) of participants could identify how to correctly take PrEP, which was
156 selecting the response: 'taking a pill daily for 7 days before an HIV exposure and then
157 ongoing for at least 28 days'. There were 24.8% (101/407) of respondents unsure of how
158 effective PrEP was at preventing HIV, while 68.8% (280/407) correctly identified that PrEP is
159 >80% effective at preventing HIV.

160

161 **Prescribing practices**

162 About two-thirds (63.4%, 258/407) of GPs had ever prescribed PrEP. Only 45.2% (184/407)
163 felt confident with prescribing PrEP. The proportion of participants who prescribed PrEP 'less
164 than once a year' was 44.7% (182/407), 'at least once a year' was 13% (53/407), 'at least once
165 every three months' was 18.2% (74/407), 'at least once a month' was 8.8% (36/407), and 'at
166 least once a week' was 9.2% (37/407). Sixty-seven percent (273/407) of participants have had
167 a client ask them for PrEP before. Table 2 outlines when participants last took a sexual history.

168


169 **Prescribing to certain groups**

170 Figure 1 details the proportion of respondents who stated they would be likely, highly likely
171 or certain to prescribe to certain groups. Some notable results include sexually active males
172 who have anal sex with males without condoms (92.6%, 377/407) and sex workers in

173 Australian (74.9%, 305/407).

174

175 **Figure 1: Likelihood of prescribing PrEP to certain client groups (%).**



176

177 MSM = Men who have sex with Men.

178

179

180 **Factors associated with stated efficacy of PrEP > 80% and ever prescribing PrEP.**

181 Table 2 demonstrates that efficacy of PrEP >80% was associated with younger age (Adjusted
182 odds ratio (AOR) 0.97 per additional year of age, 95% confidence interval(CI): 0.94-0.99),
183 and negatively associated with taking last sexual history 'more than a month ago' (AOR 0.35,
184 95%CI: 0.17-0.71) compared with 'less than a week ago', and positively associated with
185 extra training in in sexual health (AOR 1.83, 95%CI: 1.09-3.06), and S100 prescriber status
186 (AOR 3.38, 95%CI: 1.44-8.00).

187 Table 3 demonstrates that ever prescribing PrEP was negatively associated with increasing
188 age (AOR 0.96, 95%CI: 0.93-0.98), and positively associated with working in the inner city
189 compared to metropolitan or suburban area (AOR 3.40, 95%CI: 1.65-7.03), with extra
190 training in sexual health (AOR 2.57, 95%CI: 1.54-4.29) and negatively associated with being a
191 GP in Western Australia (AOR 0.22, 95%CI: 0.09-0.52) compared to Victoria. Most (77.6%,
192 316/407) participants reported PrEP education should be an essential part of HIV education
193 at GP visits.

194 **Table 2 – Factors associated with stated efficacy of PrEP > 80% (N=371)**

Factors	n/N (%)	Odds ratio (95% CI)	P-value	AOR (95% CI)	P-value
Age (years)		0.97 (0.95 - 1.00)	0.02	0.97 (0.94 - 0.99)	0.009
Gender					
Female	183/272 (67)	1			
Male	75/99 (76)	1.52 (0.90 - 2.57)	0.11		
Location					
Metropolitan or Suburban	112/174 (64)	1			
Inner City	59/74 (80)	2.18 (1.14 – 4.15)	0.02		
Regional	55/77 (71)	1.38 (0.77 - 2.48)	0.28		
Rural	32/46 (70)	1.27 (0.63 - 2.55)	0.51		
State/territory of practice					
Victoria	105/146 (72)	1			
New South Wales	56/78 (72)	0.99 (0.54 - 1.83)	0.98		
Queensland	37/59 (63)	0.66 (0.35 - 1.24)	0.19		
Western Australia	22/34 (65)	0.72 (0.32 - 1.58)	0.40		
South Australia	25/36 (69)	0.89 (0.40 - 1.97)	0.76		
Northern Territory	4/5 (80)	1.56 (0.17 - 14.39)	0.69		
Tasmania	9/13 (69)	0.88 (0.26 - 3.01)	0.83		

Duration of practice (years)		0.97 (0.95 - 1.00)	0.05		
Extra training in sexual health					
No	145/229 (63)	1		1	
Yes	113/142 (80)	2.26 (1.38 - 3.68)	<0.01	1.83 (1.09 - 3.06)	0.02
S100 prescriber*					
No	205/311 (66)	1		1	
Yes	53/60 (88)	3.91 (1.72 - 8.91)	<0.01	3.38 (1.44 - 8.00)	0.01
Last sexual history taken from a client:					
Less than a week ago	192/258 (74)	1		1	
Less than a month ago	46/73 (63)	0.59 (0.34 - 1.02)	0.05	0.66 (0.37 - 1.17)	0.15
More than a month ago	20/40 (50)	0.34 (0.17 - 0.68)	<0.01	0.35 (0.17 - 0.71)	<0.01

195 *S100 accreditation allows GPs in Australia to prescribe specialised medications such as antiretrovirals.

196 AOR = Adjusted odds ratio; CI = confidence interval. Utilised backward elimination approach to derive the final multivariable model.

197 Variables with p-value <0.05 are in bold

198

199

200

201 Table 3 – Factors associated with ever having prescribed PrEP (N=371)

Factors	n/N	Odds ratio (95% CI)	P-value	AOR (95% CI)	P-value
Age (years)		0.97 (0.94 - 0.99)	0.01	0.96 (0.93 - 0.98)	<0.01
Gender					
Female	159/272 (58)	1		1	
Male	77/99 (78)	2.49 (1.46 - 4.23)	<0.01	2.67 (1.49 - 4.80)	<0.01
Location					
Metropolitan or Suburban	101/174 (58)	1		1	
Inner City	62/74 (84)	3.73 (1.88 - 7.43)	<0.01	3.40 (1.65 - 7.03)	<0.01
Regional	48/77 (62)	1.20 (0.69 - 2.07)	0.52	1.14 (0.62 - 2.09)	0.68
Rural	25/46 (54)	0.86 (0.45 - 1.65)	0.66	0.79 (0.38 - 1.65)	0.54
State					
Victoria	106/146 (73)	1		1	
New South Wales	51/78 (65)	0.71 (0.39 - 1.29)	0.26	0.74 (0.38 - 1.41)	0.35
Queensland	34/59 (58)	0.51 (0.27 - 0.97)	0.03	0.80 (0.40 - 1.60)	0.52
Western Australia	14/34 (41)	0.26 (0.12 - 0.57)	<0.01	0.22 (0.09 - 0.52)	<0.01
South Australia	20/36 (56)	0.47 (0.22 - 1.00)	0.05	0.47 (0.21- 1.08)	0.07
Northern Territory	3/5 (60)	0.57 (0.09 - 3.51)	0.54	0.71 (0.10 - 4.93)	0.72
Tasmania	8/13 (62)	0.60 (0.19 - 1.96)	0.40	0.54 (0.15 - 1.92)	0.34

Duration of Practise (years)		0.98 (0.96 - 1.01)	0.19		
Extra training in sexual health					
No	131/229 (57)	1		1	
Yes	105/142 (74)	2.12 (1.34 - 3.35)	<0.01	2.57 (1.54 - 4.29)	<0.01
S100 prescriber*					
No	187/311 (60)	1			
Yes	49/60 (82)	2.95 (1.47 - 5.90)	<0.01		
Last sexual history taken from a client:					
Less than a week ago	172/258 (67)	1			
Less than a month ago	43/73 (59)	0.72 (0.42 - 1.22)	0.22		
More than a month ago	21/40 (53)	0.55 (0.28 - 1.08)	0.08		

202 *S100 accreditation allows GPs in Australia to prescribe specialised medications such as antiretrovirals.

203 AOR = Adjusted odds ratio; CI = confidence interval. Utilised backward elimination approach to derive the final multivariable model.

204 Variables with p-value <0.05 are in bold

205

206


207

208 **Barriers**

209 Figure 2 details the level of impact of barriers to prescribing PrEP, with the top three
 210 barriers being: difficulty identifying clients who require PrEP / relying on clients to ask for
 211 PrEP (76.2%, 310/407), lack of knowledge about PrEP (70.3%, 286/407), and lack of time to
 212 adequately counsel regarding PrEP (69%, 281/407).

213

214 **Figure 2: Level of impact of barriers on GPs and their PrEP prescribing (%).**



215

216 Note that lines do not total to 100% because there was a 5th option for participants: 'Unsure'.

217 PrEP = Pre-exposure prophylaxis; STI = Sexually transmitted infection

218

219 Participants were allowed to write down other barriers that affected their prescribing of
 220 PrEP or that they could see affecting the prescribing of other doctors. The most common
 221 written response was problems with knowledge (30.7%, 51/166), followed by lack of clients
 222 (21.1%, 35/166) and lack of experience (15.1%, 25/166). For details on the other responses,
 223 refer to Supplementary Figure 1.

224

225 **Barriers by the frequency of prescribing**

226 Those who prescribed PrEP 'more often' (more frequent than every 3 months, including 3
 227 months) are less likely to be affected by barriers than those who prescribe 'not often' (less
 228 frequent than every 3 months). Those who prescribed 'more often' were most affected by

229 the barriers of lack of time to adequately counsel about PrEP (64.6%, 95/147), difficulty
230 identifying which patients would require PrEP/relying on the patient to ask for PrEP (64.6%,
231 95/147), difficulty in finding an entry point to asking patients about their risk of HIV/sexual
232 history' (47.6%, 70/147). Those who prescribe 'not often' were most affected by the
233 barriers: lack of knowledge about PrEP (86.8%, 204/235), difficulty identifying which
234 patients would require PrEP/relying on patients to ask for PrEP (84.7%, 199/235), lack of
235 experience or hesitation in prescribing antiretrovirals (80.4%, 189/235).

236

237

238 **DISCUSSION**

239

240 Our survey of Australian GPs contributes to the literature by demonstrating a significant
241 knowledge gap about PrEP, with only half correctly identifying how to take PrEP. A quarter
242 of participants were unsure how effective PrEP was at preventing HIV. In another Australian
243 study from 2017, only 24% of respondents were able to identify how to take PrEP correctly,
244 and 62% were unsure how effective PrEP was at preventing HIV (13). Our study highlights
245 other areas where GP knowledge of PrEP may be lacking. Three-quarters of participants
246 would likely prescribe PrEP to sex workers; however, Australian PrEP guidelines do not
247 identify sex workers as indicated for PrEP (17). Female sex workers have some of the lowest
248 HIV rates of any population in Australia, with an incidence rate of <0.1 per 100 person-years
249 (18).

250

251 Our study found only 45% of participants felt confident about prescribing PrEP, with 35%
252 stating they had never prescribed PrEP before. In contrast, a study of 45 GPs in Australia
253 found that 71% of participants did not feel confident prescribing PrEP and 93% had never
254 consulted a client about PrEP before (13). However, this study was conducted in 2017,
255 before PrEP was on the PBS.

256

257 The top three barriers that impacted our Australian GPs participants prescribing of PrEP
258 were difficulty identifying clients who would benefit from PrEP, lack of knowledge regarding

259 PrEP, and lack of time to adequately counsel regarding PrEP. These results are comparable
260 with the literature, with the main barriers identified in studies as lack of knowledge
261 regarding PrEP and difficulty identifying clients at risk of HIV (8, 10, 11, 12, 19). Difficulty
262 identifying clients who would benefit from PrEP could be addressed by having GP clinics
263 collect certain demographics as part of client registration. Many GP clinics do not have the
264 sexuality of their clients recorded (20). We recommend GP clinics should have questions
265 about clients' sexual identity and the genders of sexual partners in client registration forms.
266 Some potential negative consequences include clients being uncomfortable having this
267 information on their medical file, reception staff being aware or if partners found out. It is
268 important the forms have the option of 'choose not to disclose'.

269

270 The other major barrier is lack of time. Assessment and counselling for PrEP can quickly
271 exceed the standard 10-15-minute GP consult. An effective way of increasing the uptake of
272 an intervention in GP practice could be creating a specific time-based Medicare item
273 number (21) the main remuneration method for GPs in Australia, with this item being a
274 higher remuneration rate compared to the current item for consults over 20 minutes.
275 However, creating a specific Medicare item can be difficult. A more acceptable solution
276 could be short-term practice incentive payments (PIP), e.g. an additional \$10 for every
277 prescription of PrEP, running for 12 months. This can encourage GPs to invest time into
278 learning about PrEP. A UK systematic literature review of 35 articles found payment for
279 performance schemes increased services available and effectively motivated GPs (22). There
280 is a limitation of whether Medicare can identify private scripts of PrEP to award a PIP, as
281 over-seas born MSM are the highest risk groups for HIV (18). Most medical software can
282 generate data on scripts, so this could be a way to capture the private PrEP scripts, with the
283 data being sent to Medicare.

284

285 Factors associated with prescribing PrEP were extra training in sexual health or being an
286 S100 prescriber, working in an inner city setting, and younger age. The reason why there is
287 more prescribing in inner-city settings could be due to more sexual health clinics and high
288 caseload GPs being located in these settings. The association with younger age is likely due
289 to going through GP training more recently and being more likely to accept more

290 progressive ideas. There is a great need for more comprehensive training for GPs regarding
291 PrEP, assuming no prior knowledge and, in particular, looking at better ways of identifying
292 clients who would benefit from PrEP. This training should be constructed specifically for the
293 GP context, taking into account the standard GP consultation time of 10-15 minutes, and
294 GPs should be remunerated for the training with recommended rate of at least \$200 per
295 hour of training.

296

297 PrEP uptake could be increased by having a higher remuneration rate for the existing
298 Telehealth blood borne item number 92734/92737, to allow more Australians including in
299 regional and remote areas, to access PrEP from GPs more confident with PrEP prescribing,
300 and to encourage more GPs to learn about PrEP. Currently these item numbers are at the
301 same remuneration rate as standard Telehealth items for general health issues: \$41.40 for
302 consultation over 6 minutes.

303

304 The strength of this study was that it included GPs working in a range of settings and
305 locations within Australia. Our study should be read in light of some limitations. First, the
306 sample may not represent all GPs in Australia as it is prone to sampling bias and it is likely
307 that participants who had some interest in sexual health were more likely to participate. For
308 instance, when comparing to the Australian GP population: we had a greater proportion of
309 female GPs (70.5% vs 49%), a younger cohort (most being 0-39yo 57% vs most 40-54yo
310 37%), and most in Victoria (39.3%) vs most in NSW (24%) (4). Another limitation is our use of
311 multiple choice questions, whereas qualitative responses may have provided a more
312 accurate assessment. Our question asking for participants to identify how to take PrEP could
313 have been worded more clearly, as the answer 'taking a pill before and after an HIV
314 exposure, but only around the time of the exposure' could be interpreted as PrEP on
315 demand, however, it is technically not correct as it should specify taking 2 pills before an HIV
316 exposure. We adapted our knowledge questions from an Australian study (13) which utilises
317 a TGA approved definition for how to take PrEP, whereas PrEP on-demand is a well accepted
318 method of taking PrEP that is not TGA approved. This could have affected the accuracy of
319 our assessment of GP knowledge.

320

321 **CONCLUSION**

322 Most of our GP participants were not confident in prescribing PrEP and had difficulty
323 identifying who would require PrEP. More GP specific training on PrEP is needed, focusing
324 on PrEP knowledge, identifying suitable clients, and making it time efficient. The GPs should
325 be paid for the time to undertake this training. Further training is in itself insufficient, as the
326 wider issues facing General Practice need to be addressed, such as chronic under-funding
327 and no remuneration for training. Having questions about sexuality and the genders of
328 sexual partners collected in registration forms could help GPs identify people who would
329 benefit from PrEP. GPs are well placed to dramatically increase the number and
330 geographical coverage of PrEP prescribing, but they need further support.

331

332 **Acknowledgements**

333 The authors would like to thank the following organisations for help with distributing our
334 survey: GPs Down Under (GPDU) Facebook Group, North Western Melbourne Primary Health
335 Network, Brisbane North Primary Health Network, Victorian primary care practice-based
336 Research and Education Network (VicREN), the University of Melbourne, Dr Richard Teague,
337 Murray City Country Coast GP Training. We would also like to thank the researchers William
338 Lane, Clare Heal and Jennifer Banks, for allowing us to utilise their Questionnaire from their
339 study (13).

340 **Conflicts of Interest**

341 There are no other competing interests.

342

343 **Declaration of Funding**

344 DG is supported by a Canada Research Chair in Sexual and Gender Minority Health. EPFC and
345 JJO are each supported by an NHMRC Emerging Leadership Investigator Grant (GNT1172873
346 and GNT1193955, respectively). CKF is supported by an Australian NHMRC Leadership
347 Investigator Grant (GNT1172900).

348

349 Data statements

350 JO, EC and JW had full access to all of the data in the study. De-identified data is available on
351 reasonable request to the corresponding author.

352

353 REFERENCES

- 354 1. Service UPH. PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE
355 UNITED STATES – 2017 UPDATE A CLINICAL PRACTICE GUIDELINE. 2017.
- 356 2. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-
357 tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. *Sci*
358 *Transl Med*. 2012;4(151):151ra25.
- 359 3. UNAIDS. Ending inequalities and getting on track to end AIDS by 2030. [Available from:
360 https://www.unaids.org/sites/default/files/media_asset/2021-political-declaration_summary-10-targets_en.pdf#:~:text=Ensure%20availability%20of%20PrEP%20for%20%2810%20million%29%20people,appropriate%2C%20prioritized%2C%20people-centred%20and%20effective%20combination%20prevention%20options.
361
362
- 363 4. DHAC. General Practice Workforce (2017-2018 to 2022-2023 Financial Years). In: Care DoHA,
364 editor. 2017-2018 to 2022-2023.
- 365 5. Australasian Society for HIV VHaSHMA. ASHM Prescriber Map 2024 [Available from:
366 <https://www.ashm.org.au/prescriber-maps/>.
367
- 368 6. Health AGDo. Sexual health Medicine - 2016 factsheet 2016 [Available from:
369 <https://hwd.health.gov.au/resources/publications/factsheet-mdcl-sexual-health-2016.pdf>.
370
- 371 7. Fraser D MN, McManus H, Guy R, Grulich AE, Bavinton BR. Monitoring HIV pre-exposure
372 prophylaxis (PrEP) uptake in Australia (Issue 8). Sydney: Kirby Institute, UNSW Sydney; 2023 ISSN:
373 2653-3820. 2023.
- 374 8. Smith AKJ, Haire B, Newman CE, Holt M. Challenges of providing HIV pre-exposure
375 prophylaxis across Australian clinics: qualitative insights of clinicians. *Sex Health*. 2021;18(2):187-94.
- 376 9. Vanhamel J, Reyniers T, Wouters E, van Olmen J, Vanbaelen T, Nöstlinger C, et al. How Do
377 Family Physicians Perceive Their Role in Providing Pre-exposure Prophylaxis for HIV Prevention?—An
378 Online Qualitative Study in Flanders, Belgium. *Frontiers in Medicine*. 2022;9.
- 379 10. Villeneuve F, Cabot JM, Eymard-Duvernay S, Visier L, Tribout V, Perollaz C, et al. Evaluating
380 family physicians' willingness to prescribe PrEP. *Med Mal Infect*. 2020;50(7):606-10.
- 381 11. Rai B, Ross S, Richardson D. P051 General practitioners' (GPs') knowledge of and attitudes to
382 prescribing pre-exposure prophylaxis for HIV (PrEP): A pilot study. *BMJ Publishing Group Ltd*; 2021.
- 383 12. Chiarabini T, Lacombe K, Valin N. HIV pre-exposure chemoprophylaxis "PrEP" in general
384 practice: are there significant barriers? *Sante Publique*. 2021;33(1):101-12.
- 385 13. Lane W, Heal C, Banks J. HIV pre-exposure prophylaxis: Knowledge and attitudes among
386 general practitioners. *Aust J Gen Pract*. 2019;48(10):722-7.
- 387 14. Lazarou M, Fitzgerald L, Warner M, Downing S, Williams OD, Gilks CF, et al. Australian
388 interdisciplinary healthcare providers' perspectives on the effects of broader pre-exposure
389 prophylaxis (PrEP) access on uptake and service delivery: a qualitative study. *Sex Health*.
390 2020;17(6):485-92.
- 391 15. Monde Md. THE KAP SURVEY MODEL (KNOWLEDGE, ATTITUDES, & PRACTICES)2011
392 17/01/24. Available from: <https://www.spring-nutrition.org/publications/tool-summaries/kap-survey-model-knowledge-attitudes-and-practices>.

- 393 16. Wu J FC, Grace D, Chow EPF, Ong JJ. Agreement of and discussion with clients about
394 Undetectable equals Untransmissible (U=U) among General Practitioners in Australia: A cross-
395 sectional survey. Sexual Health CSIRO. 2023;In Press.
- 396 17. ASHM. 2021 National PrEP guidelines. 2021 26/03/23.
- 397 18. King J, McManus, H, Kwon, A, Gray, R & McGregor, S. HIV, viral hepatitis and sexually
398 transmissible infections in Australia: Annual surveillance report 2022. Sydney, Australia: UNSW
399 Sydney; 2022.
- 400 19. Vanhamel J, Reyniers T, Wouters E, van Olmen J, Vanbaelen T, Nöstlinger C, et al. How Do
401 Family Physicians Perceive Their Role in Providing Pre-exposure Prophylaxis for HIV Prevention?—An
402 Online Qualitative Study in Flanders, Belgium. *Frontiers in Medicine*. 2022;9:699.
- 403 20. Payne H. The new RACGP gender and sex standards, explained 2021 [Available from:
404 <https://www.medicalrepublic.com.au/the-new-racgp-gender-and-sex-standards-explained/57824>.
- 405 21. Holden L, Williams ID, Patterson E, Smith JW, Scuffham PA, Cheung L, et al. Uptake of
406 Medicare chronic disease management incentives - a study into service providers' perspectives. *Aust
407 Fam Physician*. 2012;41(12):973-7.
- 408 22. Ahmed K HS, Khankhara M, et al. What drives general practitioners in the UK to improve the
409 quality of care? A systematic literature review. *BMJ Open Quality*. 2021;10(1).

410